New & Noteworthy - Pharmacy Purchasing & Products Magazine
Wockhardt says US FDA has approved Fresenius Kabi-made generic Zosyn
Fresenius starts $250M U.S. site expansion | Fierce Pharma
Fresenius Kabi intros generic Alimta | Drug Store News
Biopharmaceuticals: Generic Growth - Expiring patents figure to propel massive increases in revenue. | Site Selection Online
Fresenius Kabi Launches Generic Gadoterate Meglumine Injection, Bioequivalent to Dotarem - Pharmacy Practice News
Intaxel® Injection Vial | OKDERMO Skin Care
Fresenius Kabi Introduces Cancer Copay Scheme For Generics :: Generics Bulletin
Fresenius Kabi Introduces New Generic for the Treatment of Multiple Myeloma - Fresenius Kabi USA
Fresenius Kabi Introduces Generic Iodixanol Contrast Media Agent - Fresenius Kabi USA
Fresenius Kabi Xylocaine 1% 30mL, Pack $245.00/Pack of 25 Modern Medical Products 2940-25
Fresenius Kabi Launches Icatibant Injection to Treat Acute Attacks of Hereditary Angioedema in Adults | BioSpace
Fresenius Kabi Launches Generic Cubicin - MPR
IntelliGuard + Fresenius Kabi Partnership: Fresenius Kabi Introduces RFID Smart Labels for a Range of Essential Medications – IntelliGuard
Fresenius Kabi Contract Manufacturing Corporate Profile | Pharmaceutical Outsourcing
Fresenius Kabi Announces U.S. Availability of Cancer Therapeutic Thiotepa | Business Wire
Fresenius Kabi Expands Contrast Agent Portfolio with Launch of Gadoterate Meglumine Injection, USP - Fresenius Kabi USA
Home - Fresenius Kabi Generic Contrast Agents
Fresenius Kabi - Hello Brussels & welcome all visitors to Day 3 of the Isicem 2018. Feel free to stop by our booth during expo hours today until 5pm and tomorrow from
Our Business Fields - Fresenius Kabi Global
Fresenius Kabi Introduces Generic Iodixanol Contrast Media Agent | Imaging Technology News
Generic Equivalent to Istodax Now Available - MPR
Fresenius agrees two acquisitions to bolster Kabi drugs unit | Reuters
